This agreement brings together the complementary research and development expertise of both institutions to advance innovative intellectual property from MD Anderson to improve the delivery of radiation therapy for patients with cancer

Getty Images


August 24, 2022 — The University of Texas MD Anderson Cancer Center and Empyrean Medical Systems, Inc. today announced an exclusive license and joint development agreement to advance novel technologies and products in the fields of radiation oncology and cancer therapeutics. 

This agreement brings together the complementary research and development expertise of both institutions to advance innovative intellectual property from MD Anderson to improve the delivery of radiation therapy for patients with cancer. 

“We are proud to collaborate with MD Anderson as we work toward bringing these novel technologies to light,” said Kal Fishman, founder, president, and chief executive officer of Empyrean Medical Systems. “Our goal is to develop multiple state-of-the-art products to deliver optimal radiation therapy for our clinicians and make a real difference for patients and their families.” 

Under this agreement, Empyrean obtains an exclusive license to develop and commercialize a new approach for delivering radiation therapy originally discovered by MD Anderson researchers. The Magnetically Optimized Very High Energy Electron Therapy (MOVHEET) method has the potential to significantly improve the precision of radiation delivered by machinery with a similar footprint to conventional options. 

“The combined expertise of MD Anderson and Empyrean allows us the opportunity to take advantage of dosimetric characteristics of very high energy electron beams for the treatment of malignant tumors,” said Mohammad Salehpour, Ph.D., professor of Radiation Physics at MD Anderson. “The MOVHEET system is designed from the ground up to deliver both conventional and FLASH dose rate radiotherapy with enhanced precision to increase its efficacy.” 

In addition to MOVHEET, Empyrean and MD Anderson intend to collaboratively develop additional technologies based on Empyrean’s intellectual property, all with the goal of optimizing care for patients with cancer. MD Anderson will receive an equity interest in Empyrean and is eligible to receive certain royalties and other financial considerations. 

For more information: https://www.mdanderson.org/ 


Related Content

News | Coronavirus (COVID-19)

February 8, 2023 — New data published in the Journal of Clinical Oncology further quantify the vast lingering impact of ...

Time February 08, 2023
arrow
News | Radiation Oncology

February 7, 2023 — During World Cancer Day (February 4), the Elekta Foundation celebrated its first year by highlighting ...

Time February 07, 2023
arrow
News | Radiation Oncology

February 7, 2023 — Primary lung neuroendocrine tumors are very rare tumors that represent about 1-2% of all lung cancer ...

Time February 07, 2023
arrow
News | Proton Therapy

February 7, 2023 — IBA (Ion Beam Applications S.A.), a world leader in particle accelerator technology, today announces ...

Time February 07, 2023
arrow
News | Radiation Therapy

February 6, 2023 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time February 06, 2023
arrow
News | Radiation Therapy

February 2, 2023 — DenseBreast-info.org (DBI) announced the results of the study, “Effect of an Educational Intervention ...

Time February 02, 2023
arrow
News | Radiation Therapy

February 2, 2023 — RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug ...

Time February 02, 2023
arrow
News | Radiation Oncology

February 2, 2023 — The V Foundation, a top cancer research charity, has announced the establishment of a new grant ...

Time February 02, 2023
arrow
News | Radiation Therapy

February 1, 2023 — Radiotherapy is a crucial component of cancer treatment, used to shrink or destroy tumors with high ...

Time February 01, 2023
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a recap of what ITN viewers found most interesting during the month of January: 1. A Look at the Changes in 2023 ...

Time February 01, 2023
arrow
Subscribe Now